Adia Nutrition Inc
adianutrition.comAdia Nutrition Inc (OTC: ADIA) is a biologic products company (SIC 2836) that develops and sells umbilical cord stem cell treatments, biologic products, and nutritional supplements. Revenue comes from the sale of supplements, medical procedures, biologic products, ancillary products, shipping, and sublease income. The company operates Adia Med of Winter Park, LLC as its clinical treatment facility and Adia Labs, LLC as its biologic product procurement and sales arm. Revenues were $700,508 for the year ended December 31, 2025, compared to $6,380 for the year ended December 31, 2024. The company was revived under Nevada charter in June 2022 following a custodianship proceeding, with Nikki Lee appointed as sole officer and director at that time. The company filed one provisional patent in 2025 and holds trademarks on two products. ADIA operates at an early commercial stage with net losses reported in each disclosed period.
Products & Services
Umbilical Cord Blood Stem Cell (UCB-SC) treatments marketed as AdiaVita, containing at least 100 million stem cells and 3 trillion exosomes per unit. Products registered with the FDA under Section 361 of the Public Health Service Act (PHSA) and 21 CFR Part 1271. Treatments address orthopedic issues, pain management, and wound repair. The company also sells nutritional supplements. One provisional patent was filed in 2025.
Revenue Model
Transactional revenue from the sale of supplements, medical procedures, biologic products, ancillary products, shipping and delivery, other services, and sublease income. No subscription or royalty revenue model is disclosed in the 10-K filed March 31, 2026.
Customers & Markets
Healthcare providers and health insurance companies are the stated partnership targets. End markets include regenerative medicine, orthopedics, pain management, and wound repair. No customer concentration data or customer counts are disclosed in the filing.
Geographic Exposure
Operations based in Winter Park, Florida, with a stated plan for a nationwide rollout of satellite clinic locations. No international operations are disclosed in the filing.
Source: SEC 10-K, filed 2026-03-31
Financial Snapshot
Loading...
